Larrayoz, Marta http://orcid.org/0000-0001-6097-8244
Garcia-Barchino, Maria J.
Celay, Jon http://orcid.org/0000-0002-2017-4206
Etxebeste, Amaia http://orcid.org/0000-0003-4408-0981
Jimenez, Maddalen
Perez, Cristina
Ordoñez, Raquel
Cobaleda, Cesar http://orcid.org/0000-0003-3807-9204
Botta, Cirino
Fresquet, Vicente http://orcid.org/0000-0003-1511-8354
Roa, Sergio http://orcid.org/0000-0003-1095-0715
Goicoechea, Ibai http://orcid.org/0000-0002-5329-2225
Maia, Catarina
Lasaga, Miren
Chesi, Marta http://orcid.org/0000-0002-4024-8225
Bergsagel, P. Leif http://orcid.org/0000-0003-1523-7388
Larrayoz, Maria J.
Calasanz, Maria J. http://orcid.org/0000-0002-0374-3008
Campos-Sanchez, Elena
Martinez-Cano, Jorge http://orcid.org/0000-0001-6809-5489
Panizo, Carlos
Rodriguez-Otero, Paula
Vicent, Silvestre http://orcid.org/0000-0002-9457-6881
Roncador, Giovanna
Gonzalez, Patricia
Takahashi, Satoru http://orcid.org/0000-0002-8540-7760
Katz, Samuel G.
Walensky, Loren D.
Ruppert, Shannon M.
Lasater, Elisabeth A.
Amann, Maria
Lozano, Teresa
Llopiz, Diana
Sarobe, Pablo
Lasarte, Juan J. http://orcid.org/0000-0003-1641-3881
Planell, Nuria
Gomez-Cabrero, David
Kudryashova, Olga http://orcid.org/0000-0003-3320-7764
Kurilovich, Anna http://orcid.org/0000-0002-3952-8609
Revuelta, Maria V. http://orcid.org/0000-0002-7922-0713
Cerchietti, Leandro http://orcid.org/0000-0003-0608-1350
Agirre, Xabier http://orcid.org/0000-0002-6558-9560
San Miguel, Jesus http://orcid.org/0000-0002-9183-4857
Paiva, Bruno http://orcid.org/0000-0003-1977-3815
Prosper, Felipe http://orcid.org/0000-0001-6115-8790
Martinez-Climent, Jose A. http://orcid.org/0000-0002-7938-3950
Article History
Received: 2 February 2022
Accepted: 9 December 2022
First Online: 16 March 2023
Competing interests
: M.C. has received honoraria from participation in advisory boards from Oncopeptides, Novartis, Janssen and Pfizer; and has licensed intellectual property through Mayo Clinical Ventures 2013-058 ‘Genetically engineered mouse model of MM without LoxP sites (Vk*MycCwoLoxP) and transplantable cell lines’. L.B. has received honoraria from participation in advisory boards from Oncopeptides, Novartis, Janssen and Pfizer; and has licensed intellectual property through Mayo Clinical Ventures 2013-058 ‘Genetically engineered mouse model of MM without LoxP sites (Vk*MycCwoLoxP) and transplantable cell lines’. P.R.-O. has received honoraria from advisory boards from Pfizer, BMS, Janssen, GSK, Kite, Sanofi and Oncopeptides; and honoraria from lectures from GSK, Janssen, BMS, Regeneron, Amgen and Oncopeptides. S.M.R. is an employee of Roche/Genentech. E.A.L. is an employee of Roche/Genentech. M.A. is an employee of Roche, and has patent applications on CD25 monoclonal antibody with relevance to this work: WO/2018/167104 and US20190284287 (filed by Cancer Research Technology Limited and Tusk Therapeutics). M.A. has shares in the companies to which the patent belongs. O.K. is an employee of BostonGene. J.S.M. is a consultant and an advisory board member for (on behalf of his Institution) Amgen, BMS, Celgene, Haemalogix, Janssen, MSD, Novartis, Takeda, Sanofi, Roche, Abbvie, GlaxoSmithKline, Regeneron, SecuraBio and Karyopharm. B.P. reports honoraria for lectures from and membership on advisory boards with Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb-Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda; unrestricted grants from Bristol Myers Squibb-Celgene, EngMab, Roche, Sanofi and Takeda; and consultancy for Bristol Myers Squibb-Celgene, Janssen, Sanofi and Takeda. J.A.M.-C. reports funding for research from Roche/Genentech, Bristol Myers Squibb-Celgene, Janssen, Priothera and Palleon. A patent on the generation and use of the mouse MM models as immunotherapy platforms, entitled ‘Genetically engineered animal models for multiple myeloma’ (application no. EP22382736.1) was filed on 27 July 2022. The remaining authors declare no competing interests.